0001493152-22-013869.txt : 20220516 0001493152-22-013869.hdr.sgml : 20220516 20220516163115 ACCESSION NUMBER: 0001493152-22-013869 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220516 DATE AS OF CHANGE: 20220516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERPACE BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001054102 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 222919486 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-24249 FILM NUMBER: 22929781 BUSINESS ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 412-224-6100 MAIL ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Interpace Diagnostics Group, Inc. DATE OF NAME CHANGE: 20151223 FORMER COMPANY: FORMER CONFORMED NAME: PDI INC DATE OF NAME CHANGE: 20021113 FORMER COMPANY: FORMER CONFORMED NAME: PROFESSIONAL DETAILING INC DATE OF NAME CHANGE: 19980129 10-Q 1 form10-q.htm
0001054102 false Q1 --12-31 0001054102 2022-01-01 2022-03-31 0001054102 2022-05-06 0001054102 2022-03-31 0001054102 2021-12-31 0001054102 us-gaap:SeriesBPreferredStockMember 2022-03-31 0001054102 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001054102 2021-01-01 2021-03-31 0001054102 us-gaap:CommonStockMember 2021-12-31 0001054102 us-gaap:CommonStockMember 2020-12-31 0001054102 us-gaap:TreasuryStockMember 2021-12-31 0001054102 us-gaap:TreasuryStockMember 2020-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001054102 us-gaap:RetainedEarningsMember 2021-12-31 0001054102 us-gaap:RetainedEarningsMember 2020-12-31 0001054102 us-gaap:ParentMember 2021-12-31 0001054102 us-gaap:ParentMember 2020-12-31 0001054102 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001054102 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001054102 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001054102 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001054102 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001054102 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001054102 us-gaap:ParentMember 2022-01-01 2022-03-31 0001054102 us-gaap:ParentMember 2021-01-01 2021-03-31 0001054102 us-gaap:CommonStockMember 2022-03-31 0001054102 us-gaap:CommonStockMember 2021-03-31 0001054102 us-gaap:TreasuryStockMember 2022-03-31 0001054102 us-gaap:TreasuryStockMember 2021-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001054102 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001054102 us-gaap:RetainedEarningsMember 2022-03-31 0001054102 us-gaap:RetainedEarningsMember 2021-03-31 0001054102 us-gaap:ParentMember 2022-03-31 0001054102 us-gaap:ParentMember 2021-03-31 0001054102 2020-12-31 0001054102 2021-03-31 0001054102 IDXG:AmpersandNotesMember 2021-01-07 0001054102 IDXG:OneThousandThreeFifteenCapitalNoteMember 2021-01-07 0001054102 IDXG:AmpersandNotesMember 2021-05-10 0001054102 IDXG:OneThousandThreeFifteenCapitalNoteMember 2021-05-10 0001054102 IDXG:ComericaBankMember 2021-10-31 0001054102 IDXG:TermLoanMember IDXG:BroadOakMember 2021-10-31 0001054102 IDXG:TermLoanMember IDXG:BroadOakMember us-gaap:ConvertibleDebtMember 2022-05-05 0001054102 us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-03-31 0001054102 IDXG:BioPharmaAcquisitionMember 2019-07-01 2019-07-31 0001054102 IDXG:BioPharmaAcquisitionMember 2019-07-31 0001054102 IDXG:BioPharmaAcquisitionMember 2022-03-31 0001054102 IDXG:OptionsMember 2022-01-01 2022-03-31 0001054102 IDXG:OptionsMember 2021-01-01 2021-03-31 0001054102 IDXG:RestrictedStockUnitsRSUsMember 2022-01-01 2022-03-31 0001054102 IDXG:RestrictedStockUnitsRSUsMember 2021-01-01 2021-03-31 0001054102 IDXG:WarrantsMember 2022-01-01 2022-03-31 0001054102 IDXG:WarrantsMember 2021-01-01 2021-03-31 0001054102 IDXG:AsuragenAcquisitionMember IDXG:ThyroidMember 2022-03-31 0001054102 IDXG:AsuragenAcquisitionMember IDXG:ThyroidMember 2021-12-31 0001054102 IDXG:AsuragenAcquisitionMember IDXG:ThyroidMember 2022-01-01 2022-03-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:PancreasTestMember 2022-03-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:PancreasTestMember 2021-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:PancreasTestMember 2022-01-01 2022-03-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:BarrettsTestMember 2022-03-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:BarrettsTestMember 2021-12-31 0001054102 IDXG:RedPathAcquisitionMember IDXG:BarrettsTestMember 2022-01-01 2022-03-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:TrademarksMember 2022-03-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:TrademarksMember 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:TrademarksMember 2022-01-01 2022-03-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:CustomerRelationshipsMember 2022-03-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-12-31 0001054102 IDXG:BioPharmaAcquisitionMember us-gaap:CustomerRelationshipsMember 2022-01-01 2022-03-31 0001054102 IDXG:CLIALabMember 2022-03-31 0001054102 IDXG:CLIALabMember 2021-12-31 0001054102 IDXG:CLIALabMember 2022-01-01 2022-03-31 0001054102 IDXG:AsuragenMember 2022-03-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember IDXG:AsuragenMember 2022-03-31 0001054102 us-gaap:FairValueInputsLevel1Member IDXG:AsuragenMember 2022-03-31 0001054102 us-gaap:FairValueInputsLevel2Member IDXG:AsuragenMember 2022-03-31 0001054102 us-gaap:FairValueInputsLevel3Member IDXG:AsuragenMember 2022-03-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2022-03-31 0001054102 us-gaap:FairValueInputsLevel1Member 2022-03-31 0001054102 us-gaap:FairValueInputsLevel2Member 2022-03-31 0001054102 us-gaap:FairValueInputsLevel3Member 2022-03-31 0001054102 IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel1Member IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel2Member IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel3Member IDXG:AsuragenMember 2021-12-31 0001054102 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2021-12-31 0001054102 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001054102 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001054102 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001054102 IDXG:AsuragenMember 2022-01-01 2022-03-31 0001054102 IDXG:UnderwriterWarrantsMember 2021-12-31 0001054102 IDXG:UnderwriterWarrantsMember 2022-01-01 2022-03-31 0001054102 IDXG:UnderwriterWarrantsMember 2022-03-31 0001054102 IDXG:BroadOakLoanMember 2021-12-31 0001054102 IDXG:BroadOakLoanMember 2022-01-01 2022-03-31 0001054102 IDXG:BroadOakLoanMember 2022-03-31 0001054102 IDXG:OpearatingLeaseMember 2022-03-31 0001054102 IDXG:FinancingLeaseMember 2022-03-31 0001054102 IDXG:StockIncentivePlanMember 2022-01-01 2022-03-31 0001054102 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001054102 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001054102 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001054102 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-03-31 0001054102 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001054102 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001054102 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001054102 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001054102 IDXG:TermLoanMember IDXG:BroadOakMember 2021-10-29 0001054102 IDXG:TermLoanMember IDXG:AmpersandTwoThousandEighteenMember 2021-10-28 2021-10-29 0001054102 IDXG:TermLoanMember IDXG:AmpersandTwoThousandEighteenMember 2021-10-29 0001054102 IDXG:LoanAndSecurityAgreementMember IDXG:ComericaBankMember 2021-10-29 0001054102 IDXG:LoanAndSecurityAgreementMember IDXG:ComericaBankMember 2021-10-28 2021-10-29 0001054102 IDXG:SecurityAgreementMember IDXG:OneThousandThreeFifteenCapitalNoteMember 2021-01-07 0001054102 IDXG:SecurityAgreementMember IDXG:AmpersandNoteMember 2021-05-10 0001054102 IDXG:SecurityAgreementMember IDXG:OneThousandThreeFifteenCapitalNoteMember 2021-05-10 0001054102 IDXG:AmpersandMember IDXG:TermLoanMember 2021-09-28 2021-09-29 0001054102 IDXG:OneThousandThreeFifteenCapitalMember IDXG:TermLoanMember 2021-09-28 2021-09-29 0001054102 IDXG:SecurityPurchaseAndExchangeAgreementMember us-gaap:SeriesBPreferredStockMember 2020-01-09 2020-01-10 0001054102 IDXG:SecurityPurchaseAndExchangeAgreementMember us-gaap:SeriesBPreferredStockMember IDXG:OneThreeOneFiveCapitalMember 2020-01-09 2020-01-10 0001054102 IDXG:SecurityPurchaseAndExchangeAgreementMember us-gaap:SeriesBPreferredStockMember IDXG:AmpersandLimitedPartnershiMember 2020-01-09 2020-01-10 0001054102 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001054102 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001054102 IDXG:PrivatePlacementWarrantsMember 2022-01-01 2022-03-31 0001054102 IDXG:PrivatePlacementWarrantsMember 2022-03-31 0001054102 IDXG:PrivatePlacementWarrantsMember 2021-12-31 0001054102 IDXG:RedPathWarrantsMember 2022-01-01 2022-03-31 0001054102 IDXG:RedPathWarrantsMember 2022-03-31 0001054102 IDXG:RedPathWarrantsMember 2021-12-31 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2022-01-01 2022-03-31 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2022-03-31 0001054102 IDXG:BaseandOverallotmentWarrantsMember 2021-12-31 0001054102 IDXG:WarrantsIssuedMember 2022-01-01 2022-03-31 0001054102 IDXG:WarrantsIssuedMember 2022-03-31 0001054102 IDXG:WarrantsIssuedMember 2021-12-31 0001054102 IDXG:UnderwritersWarrantsTwoMember 2022-01-01 2022-03-31 0001054102 IDXG:UnderwritersWarrantsTwoMember 2022-03-31 0001054102 IDXG:UnderwritersWarrantsTwoMember 2021-12-31 0001054102 us-gaap:WarrantMember 2022-03-31 0001054102 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001054102 IDXG:ComericaLoanAgreementMember IDXG:ComericaBankMember IDXG:TermLoanMember 2021-10-13 0001054102 IDXG:LoanAndSecurityAgreementMember 2021-10-13 0001054102 IDXG:LoanAndSecurityAgreementMember 2021-10-12 2021-10-13 0001054102 IDXG:LoanAndSecurityAgreementMember us-gaap:AccountsReceivableMember 2021-10-13 0001054102 srt:ScenarioForecastMember IDXG:LoanAndSecurityAgreementMember 2022-06-30 0001054102 IDXG:LoanAndSecurityAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-10-12 2021-10-13 0001054102 us-gaap:RevolvingCreditFacilityMember 2021-10-13 0001054102 2022-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure IDXG:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________ to _______________

 

Commission File Number: 000-24249

 

Interpace Biosciences, Inc.
(Exact name of registrant as specified in its charter)

 

Delaware   22-2919486

(State or other jurisdiction of

Incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

Morris Corporate Center 1, Building C
300 Interpace Parkway, Parsippany, NJ 07054
(Address of principal executive offices and zip code)
 
(855) 776-6419
(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N//A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐
Non-accelerated filer   Smaller reporting company
    Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

 

Class   Shares Outstanding May 6, 2022
Common Stock, par value $0.01 per share   4,229,939

 

 

 

 

 

 

INTERPACE BIOSICENCES, INC.

FORM 10-Q FOR PERIOD ENDED MARCH 31, 2022

TABLE OF CONTENTS

 

   

Page

No.

     
  PART I - FINANCIAL INFORMATION  
     
Item 1. Unaudited Interim Condensed Consolidated Financial Statements 3
     
  Condensed Consolidated Balance Sheets at March 31, 2022 (unaudited) and December 31, 2021 3
     
  Condensed Consolidated Statements of Operations for the three- month periods ended March 31, 2022 and 2021 (unaudited) 4
     
  Condensed Consolidated Statements of Stockholders’ Deficit for the three- month periods ended March 31, 2022 and 2021 (unaudited) 5
     
  Condensed Consolidated Statements of Cash Flows for the three- month periods ended March 31, 2022 and 2021 (unaudited) 6
     
  Notes to Unaudited Condensed Consolidated Financial Statements 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 24
   
Item 3. Quantitative and Qualitative Disclosures About Market Risk 32
     
Item 4. Controls and Procedures 32
     
  PART II - OTHER INFORMATION  
     
Item 1. Legal Proceedings 32
   
Item 1A. Risk Factors 32
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32
     
Item 3. Defaults Upon Senior Securities 33
     
Item 4. Mine Safety Disclosures 33
     
Item 5. Other Information 33
     
Item 6. Exhibits 33
     
Signatures 34

 

2

 

 

PART I. FINANCIAL INFORMATION

 

INTERPACE BIOSCIENCES, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

   March 31,   December 31, 
   2022   2021 
   (unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $2,850   $3,064 
Restricted cash   250    250 
Accounts receivable, net of allowance for doubtful accounts of $72 and $72, respectively   7,241    6,158 
Other current assets   2,777    2,694 
Total current assets   13,118    12,166 
Property and equipment, net   6,145    6,349 
Other intangible assets, net   6,751    7,287 
Goodwill   8,433    8,433 
Operating lease right of use assets   3,760    4,032 
Other long-term assets   151    160 
Total assets  $38,358   $38,427 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities:          
Accounts payable  $3,951   $2,694 
Accrued salary and bonus   3,461    3,024 
Other accrued expenses   8,692    9,198 
Current liabilities from discontinued operations   766    766 
Total current liabilities   16,870    15,682 
Contingent consideration   1,345    1,383 
Operating lease liabilities, net of current portion   2,928    3,154 
Line of credit   2,500    1,500 
Note payable at fair value   7,835    7,942 
Other long-term liabilities   4,685    4,648 
Total liabilities   36,163    34,309 
           
Commitments and contingencies (Note 8)   -     -  
           
Preferred stock, $.01 par value; 5,000,000 shares authorized, 47,000 shares Series B issued and outstanding   46,536    46,536 
           
Stockholders’ deficit:          
Common stock, $.01 par value; 100,000,000 shares authorized; 4,272,308 and 4,228,169 shares issued, respectively; 4,226,422 and 4,195,412 shares outstanding, respectively   404    403 
Additional paid-in capital   186,489    186,106 
Accumulated deficit   (229,306)   (227,059)
Treasury stock, at cost (45,886 and 32,757 shares, respectively)   (1,928)   (1,868)
Total stockholders’ deficit   (44,341)   (42,418)

Total liabilities and stockholders’ deficit

  $

(8,178

)  $

(8,109

)

Total liabilities, preferred stock and stockholders’ deficit

  $

38,358

   $

38,427

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

3

 

 

INTERPACE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited, in thousands, except for per share data)

 

   2022   2021 
   Three Months Ended March 31, 
   2022   2021 
         
Revenue, net  $10,377   $9,833 
Cost of revenue (excluding amortization of $536 and $1,112, respectively)   5,384    5,316 
Gross profit   4,993    4,517 
Operating expenses:          
Sales and marketing   2,416    2,351 
Research and development   299    637 
General and administrative   3,690    2,979 
Transition expense   85    1,253 
Acquisition related amortization expense   536    1,112 
Total operating expenses   7,026    8,332 
           
Operating loss   (2,033)   (3,815)
Interest accretion expense   (121)   (135)
Related party interest   -    (92)
Note payable interest   (180)   - 
Other income (expense), net   159    (96)
Loss from continuing operations before tax   (2,175)   (4,138)
Provision for income taxes   18    15 
Loss from continuing operations   (2,193)   (4,153)
           
Loss from discontinued operations, net of tax   (54)   (54)
           
Net loss  $(2,247)  $(4,207)
           
Basic and diluted loss per share of common stock:          
From continuing operations  $(0.52)  $(1.02)
From discontinued operations   (0.01)   (0.01)
Net loss per basic and diluted share of common stock  $(0.53)  $(1.03)
Weighted average number of common shares and common share equivalents outstanding:          
Basic   4,208    4,089 
Diluted   4,208    4,089 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

4

 

 

INTERPACE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(unaudited, in thousands)

 

   Shares   Amount   Shares   Amount 
   For The Three Months Ended   For The Three Months Ended 
   March 31, 2022   March 31, 2021 
   Shares   Amount   Shares   Amount 
Common stock:                    
Balance at January 1   4,228   $403    4,075   $402 
Common stock issued   35    1    9    - 
Restricted stock issued   -    -    12    - 
Common stock issued through ESPP   9    -    36    - 
Balance at March 31   4,272    404    4,132    402 
Treasury stock:                    
Balance at January 1   33    (1,868)   20    (1,773)
Treasury stock purchased   13    (60)   -    - 
Balance at March 31   46    (1,928)   20    (1,773)
Additional paid-in capital:                    
Balance at January 1        186,106         184,404 
Common stock issued        58         108 
Stock-based compensation expense        325         286 
Balance at March 31        186,489         184,798 
Accumulated deficit:                    
Balance at January 1        (227,059)        (212,116)
Net loss        (2,247)        (4,207)
Balance at March 31        (229,306)        (216,323)
                     
Total stockholders’ deficit       $(44,341)       $(32,896)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5

 

 

INTERPACE BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited, in thousands)

 

   2022   2021 
` 

For The Three Months Ended March 31,

 
   2022   2021 
         
Cash Flows From Operating Activities          
Net loss  $(2,247)  $(4,207)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   781    1,532 
Interest accretion expense   121    135 
Bad debt (recovery) expense   -    (140)
Mark to market on warrants   (63)   41 
Amortization of deferred financing fees   10    - 
Amortization of loan costs   -    52 
Interest - note payable   -    92 
Stock-based compensation   302    259 
ESPP expense   23    27 
Change in fair value of note payable   (107)   - 
Change in fair value of contingent consideration   -    (57)
Other gains and expenses, net   -    (3)
Changes in operating assets and liabilities:          
(Increase) decrease in accounts receivable   (1,083)   317 
Increase in other current assets   (83)   (253)
Increase in other long-term assets   (1)   - 
Increase (decrease) in accounts payable   1,235    (1,534)
Increase (decrease) in accrued salaries and bonus   377    (988)
Decrease in accrued liabilities   (556)   (293)
Increase in long-term liabilities   37    14 
Net cash used in operating activities   (1,254)   (5,006)
           
Cash Flows From Investing Activity          
Purchase of property and equipment   (19)   - 
Sale of property and equipment   -    39 
Net cash (used in) provided by investing activities   (19)   39 
           
Cash Flows From Financing Activities          
Issuance of common stock, net of expenses   59    108 
Loan proceeds - related parties   -    5,000 
Financing fees - related party   -    (74)
Borrowings on line of credit   1,000    - 
Net cash provided by financing activities   1,059    5,034 
           
Net (decrease) increase in cash, cash equivalents and restricted cash   (214)   67 
Cash, cash equivalents and restricted cash – beginning   3,314    3,372 
Cash, cash equivalents and restricted cash – ending  $3,100   $3,439 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6

 

 

INTERPACE BIOSCIENCES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Tabular information in thousands, except per share amounts)

 

1. OVERVIEW

 

Nature of Business

 

Interpace Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs.

 

COVID-19 pandemic

 

The COVID-19 pandemic, together with related precautionary measures, continues to impact portions of the regions in which we operate. These regions are attempting to address the COVID-19 pandemic in varying ways, including stay-at-home orders, temporarily closing businesses, restricting gatherings, restricting travel, and mandating social distancing and face coverings. The level and nature of the disruption caused by COVID-19 is unpredictable, may be cyclical and long-lasting and may vary from location to location.

 

The continuing impact that the COVID-19 pandemic will have on our operations, including duration, severity and scope, remains highly uncertain and cannot be fully predicted at this time. While we believe we have generally recovered from the adverse impact that the COVID-19 pandemic had on our business during 2020, we believe that the COVID-19 pandemic could continue to adversely impact our results of operations, cash flows and financial condition in the future.

 

We continue to monitor the COVID-19 pandemic and the guidance that is being provided by relevant federal, state and local public health authorities and may take additional actions based upon their recommendations. It is possible that we may have to make adjustments to our operating plans in reaction to developments that are beyond our control.

 

Lab closures experienced thus far by the Company have consisted of periodic, temporary work stoppages to clean and disinfect the labs. However, this could change in the future based upon conditions caused by the pandemic. Inflation and supply chain disruptions, whether caused by restrictions or slowdowns in shipping or logistics, increases in demand for certain goods used in our operations, or otherwise, could impact our operations in the near term. For the foreseeable future, however, we do not anticipate supply chain shortages of critical supplies.

 

We have contingency plans in place and will continue to monitor and update them in order to mitigate pandemic-related, adverse financial impacts upon our business.

 

Transition costs

 

Transition expenses are primarily related to the Rutherford, New Jersey lab closing and subsequent move to Morrisville, North Carolina, which was completed during the first half of Fiscal 2021, as well as other cost-saving initiatives consisting primarily of reductions in headcount and the implementation of a new laboratory information system. To optimize the operations of laboratory operations within our pharma services, we transitioned activities from the Rutherford facility to our Morrisville facility. The transition included the transfer of personnel, expansion of the Morrisville facility and validation of transferred processes.

 

7

 

 

2. BASIS OF PRESENTATION

 

The accompanying unaudited interim condensed consolidated financial statements and related notes (the “Interim Financial Statements”) should be read in conjunction with the consolidated financial statements of the Company and its wholly-owned subsidiaries (Interpace Diagnostics Lab Inc., Interpace Diagnostics Corporation, Interpace Pharma Solutions, Inc. and Interpace Diagnostics, LLC), and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities & Exchange Commission (“SEC”) on March 31, 2022 and as amended on April 29, 2022.

 

The condensed Interim Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed Interim Financial Statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements. Discontinued operations include the Company’s wholly owned subsidiaries: Group DCA, LLC, InServe Support Solutions; and TVG, Inc. and its Commercial Services business unit which was sold on December 22, 2015. All significant intercompany balances and transactions have been eliminated in consolidation. Operating results for the three-month period ended March 31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022.

 

3. GOING CONCERN

 

The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.

 

For the three months ended March 31, 2022, we had an operating loss of $2.0 million. As of March 31, 2022, we had cash, cash equivalents and restricted cash of $3.1 million, total current assets of $13.1 million and current liabilities of $16.9 million. As of May 6, 2022, we had approximately $3.7 million of cash on hand, excluding restricted cash.

 

In January 2022, the Company announced that the Centers for Medicare & Medicaid Services, or CMS, issued a new billing policy whereby CMS will no longer reimburse for the use of the Company’s ThyGeNEXT® and ThyraMIR® tests when billed together by the same provider/supplier for the same beneficiary on the same date of service. On February 28, 2022, the Company announced that the National Correct Coding Initiative (NCCI) program issued a response on behalf of CMS stating that the January 2022 billing policy reimbursement change for ThyGeNEXT® (0245U) and ThyraMIR® (0018U) tests has been retroactively reversed to January 1, 2022. CMS is currently reimbursing the Company for one of its two thyroid tests, and has agreed to retroactively reimburse for the second test once they have completed their internal administrative adjustments. We have been notified by CMS/NCCI that processing of claims for dates of service after January 1, 2022 will be completed beginning July 1, 2022. As of the date of this filing, the Company has not yet realized the full cash collection benefit of current and retroactive Thyroid testing and such cash collections may be temporarily reduced or delayed until we resolved the matter with CMS. As of the date of this filing, the Company currently anticipates that current cash and cash equivalents will be insufficient to meet its anticipated cash requirements through the next twelve months. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

8

 

 

On January 7, 2021, the Company entered into secured promissory notes in the amount of $3 million and $2 million with Ampersand (“Ampersand Note”) and 1315 Capital (“1315 Capital Note”), respectively. See Note 14, Notes Payable, of the notes to the financial statements. On May 10, 2021, the Company amended the Ampersand Note to increase the principal amount to $4.5 million and amended the 1315 Capital Note to increase the principal amount to $3.0 million. The maturity dates of the Notes were the earlier of (a) June 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Notes. On June 24, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. On August 31, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) September 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On August 31, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner.

 

On September 29, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) October 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On September 29, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner.

 

In October 2021, the Company entered into a $7.5 million revolving credit facility with Comerica. See Note 18, Revolving Line of Credit, for more details. In addition, also in October 2021, the Company entered into the $8.0 million BroadOak Term Loan, the proceeds of which were used to repay in full at their maturity the notes extended by Ampersand and 1315 Capital discussed above. See Note 14, Notes Payable, for more details. In May 2022, the Company entered into a term loan with BroadOak for an additional $2.0 million. See Note 20, Subsequent Events, for more details.

 

Although the Company is targeting to achieve Adjusted EBITDA and cash flow breakeven during Fiscal 2022, we may not generate positive cash flows from operations for the year ending December 31, 2022. We intend to meet our ongoing capital needs by using our available cash and availability under the Comerica Loan Agreement, as well as through revenue growth and margin improvement; collection of accounts receivable; containment of costs; and the potential use of other financing options. However, if we are unable to meet the financial covenants under the Comerica Loan Agreement, the revolving line of credit and notes payable will become due and payable immediately.

 

In January 2022, the Company’s registration statement for a rights offering filed with the Securities and Exchange Commission (SEC) became effective; however, the rights offering was subsequently terminated in January 2022. The Company is currently exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources in order to provide additional liquidity and expand the business through acquisitions or other strategic transactions. With the Company’s delisting from Nasdaq in February 2021, its ability to raise additional capital on terms acceptable to the Company has been adversely impacted. There can be no assurance that the Company will be successful in obtaining such funding on terms acceptable to the Company.

 

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Accounting Estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates.

 

9

 

 

Revenue Recognition

 

Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience.

 

For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which affects net revenue in the period such variances become known.

 

For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract while performance-related obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.

 

Financing and Payment

 

For non-Medicare claims, our payment terms vary by payer category. Payment terms for direct-payers in our clinical services are typically thirty days and in our pharma services, up to sixty days. Commercial third-party-payers are required to respond to a claim within a time period established by their respective state regulations, generally between thirty to sixty days. However, payment for commercial third-party claims may be subject to a denial and appeal process, which could take up to two years in some instances where multiple appeals are submitted. The Company generally appeals all denials from commercial third-party payers. We bill Medicare directly for tests performed for Medicare patients and must accept Medicare’s fee schedule for the covered tests as payment in full.

 

Costs to Obtain or Fulfill a Customer Contract

 

Sales commissions are expensed in the period in which they have been earned. These costs are recorded in sales and marketing expense in the condensed consolidated statements of operations.

 

Accounts Receivable

 

The Company’s accounts receivable represent unconditional rights to consideration and are generated using its clinical services and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.

 

10

 

 

Leases

 

The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable.

 

Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 7, Leases.

 

Other Current Assets

 

Other current assets consisted of the following as of March 31, 2022 and December 31, 2021:

 

   March 31, 2022   December 31, 2021 
   (unaudited)     
Lab supply inventory  $2,059   $1,786 
Prepaid expenses   610    800 
Other   108    108 
Total other current assets  $2,777   $2,694 

 

Long-Lived Assets, including Finite-Lived Intangible Assets

 

Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition-related amortization expense in the condensed consolidated statements of operations.

 

The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.

 

Basic and Diluted Net Loss per Share

 

A reconciliation of the number of shares of common stock, par value $0.01 per share, used in the calculation of basic and diluted loss per share for the three-month periods ended March 31, 2022 and 2021 is as follows:

 

   2022   2021 
   Three Months 
   Ended March 31, 
   2022   2021 
   (unaudited) 
Basic weighted average number of common shares   4,208    4,089 
Potential dilutive effect of stock-based awards   -    - 
Diluted weighted average number of common shares   4,208    4,089 

 

11

 

 

The Company’s Series B Preferred Stock, on an as converted basis into common stock of 7,833,334 shares for the three- months ended March 31, 2022, and the following outstanding stock-based awards and warrants, were excluded from the computation of the effect of dilutive securities on loss per share for the following periods as they would have been anti-dilutive (rounded to thousands):

 

   Three Months 
   Ended March 31, 
   2022   2021 
   (unaudited) 
Options   641    1,061 
Restricted stock units (RSUs)   319    395 
Warrants   1,339    1,405 
    2,299    2,861 

 

5. GOODWILL AND OTHER INTANGIBLE ASSETS

 

Goodwill is attributable to the acquisition of our pharma services in July 2019. The carrying value of the intangible assets acquired was $15.6 million, with goodwill of approximately $8.3 million and identifiable intangible assets of approximately $7.3 million. The goodwill balance at March 31, 2022 was $8.4 million. The net carrying value of the identifiable intangible assets from all acquisitions as of March 31, 2022 and December 31, 2021 are as follows:

 

   (Years)   Amount   Amount 
      

As of March 31, 2022

  

As of December 31, 2021

 
   Life   Carrying   Carrying 
   (Years)   Amount   Amount 
       (unaudited)     
Asuragen acquisition:            
Thyroid   9   $8,519   $8,519 
RedPath acquisition:               
Pancreas test   7    16,141    16,141 
Barrett’s test   9    6,682    6,682 
BioPharma acquisition:               
Trademarks   10    1,600    1,600 
Customer relationships   8    5,700    5,700 
                                      
CLIA Lab   2.3    609    609 
                
Total       $39,251   $39,251 
                
Accumulated Amortization        (32,500)   (31,964)
                
Net Carrying Value       $6,751   $7,287 

 

Amortization expense was approximately $0.5 million and $1.1 million for the three-month periods ended March 31, 2022 and 2021, respectively. Estimated amortization expense for the remainder of 2022 and the next four years is as follows:

 

2022   2023   2024   2025   2026 
                  
$1,607   $1,734   $873   $873   $873 

 

12

 

 

The following table displays a roll forward of the carrying amount of goodwill from December 31, 2021 to March 31, 2022:

 

   Carrying 
   Amount 
Balance as of December 31, 2021  $8,433 
Adjustments   - 
Balance as of March 31, 2022  $8,433 

 

6. FAIR VALUE MEASUREMENTS

 

Cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the condensed consolidated financial statements include contingent consideration, warrant liability and note payable. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:

 

  Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.
     
  Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.
     
  Level 3: Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

 

13

 

 

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

 

   Amount   Value   Level 1   Level 2   Level 3 
   As of March 31, 2022   Fair Value Measurements 
   Carrying   Fair   As of March 31, 2022 
   Amount   Value   Level 1   Level 2   Level 3 
           (unaudited)         
Liabilities:                         
Contingent consideration:                         
Asuragen (1)  $1,833   $1,833   $-   $-   $1,833 
Other accrued expenses:                         
Warrant liability (2)   8    8    -    -    8 
Note payable:                         
BroadOak loan   7,835    7,835    -    -    7,835 
Fair value of liabilities   $9,676   $9,676   $-   $-   $9,676 

 

   Amount   Value   Level 1   Level 2   Level 3 
   As of December 31, 2021   Fair Value Measurements 
   Carrying   Fair   As of December 31, 2021 
   Amount   Value   Level 1   Level 2   Level 3 
Liabilities:                         
Contingent consideration:                         
Asuragen (1)  $1,871   $1,871   $-   $-   $1,871 
Other accrued expenses:                         
Warrant liability (2)   71    71    -    -    71 
Note payable:                         
BroadOak loan   7,942    7,942    -    -    7,942 
Fair value of liabilities   $9,884   $9,884   $-   $-   $9,884 

 

(1)(2)See Note 9, Accrued Expenses and Long-Term Liabilities

 

In connection with the acquisition of certain assets from Asuragen, Inc., the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.

 

In connection with the BroadOak loan, the Company records the loan at fair value. The fair value of the loan is determined by a probability-weighted approach regarding the loan’s change in control feature. See Note 14, Notes Payable, for more details. The fair value measurement is based on the estimated probability of a change in control and thus represents a Level 3 measurement.

 

14

 

 

A roll forward of the carrying value of the Contingent Consideration Liability, 2017 Underwriters’ Warrants and BroadOak Loan to March 31, 2022 is as follows:

 

               Adjustment     
           Accretion/   to Fair Value/     
  

December 31,

2021

   Earned   Interest Accrued   Mark to Market   March 31, 2022 
   (unaudited) 
Asuragen  $1,871   $(159)  $121   $-   $1,833 
                          
Underwriters Warrants   71    -    -    (63)   8 
                          
BroadOak Loan   7,942    -    -    (107)   7,835 
   $9,884   $(159)  $121   $(170)  $9,676 

 

Certain of the Company’s non-financial assets, such as other intangible assets and goodwill, are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

 

7. LEASES

 

Finance lease assets are included in fixed assets, net of accumulated depreciation.

 

The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:

 

   Classification on the Balance Sheet  March 31, 2022 
      (unaudited) 
Assets        
Financing lease assets  Property and equipment, net  $620 
Operating lease assets  Operating lease right of use assets   3,760 
Total lease assets     $4,380 
         
Liabilities        
Current        
Financing lease liabilities  Other accrued expenses  $70 
Operating lease liabilities  Other accrued expenses   999 
Total current lease liabilities     $1,069 
Noncurrent        
Financing lease liabilities  Other long-term liabilities   41 
Operating lease liabilities  Operating lease liabilities, net of current portion   2,928 
Total long-term lease liabilities      2,969 
Total lease liabilities     $4,038 

 

The weighted average remaining lease term for the Company’s operating leases was 6.3 years as of March 31, 2022 and the weighted average discount rate for those leases was 6.5%. The Company’s operating lease expenses are recorded within “Cost of revenue” and “General and administrative expenses.”

 

15

 

 

The table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of March 31, 2022:

 

   Operating Leases   Financing Leases 
2022  $961   $58 
2023   897    60 
2024   567    - 
2025   402    - 
2026-2030   1,924      
Total minimum lease payments   4,751    118 
Less: amount of lease payments representing effects of discounting   824    7 
Present value of future minimum lease payments   3,927    111 
Less: current obligations under leases   999    70 
Long-term lease obligations  $2,928   $41 

 

As of March 31, 2022, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year were as follows:

 

       Less than   1 to 3   3 to 5   After 
   Total   1 Year   Years   Years   5 Years 
Operating lease obligations  $4,751   $961   $1,464   $816   $1,510 
Total  $4,751   $961   $1,464   $816   $1,510 

 

8. COMMITMENTS AND CONTINGENCIES

 

Litigation

 

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.

 

Due to the nature of the businesses in which the Company is engaged, it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products or services that the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities. There is also the risk of employment related litigation and other litigation in the ordinary course of business.

 

The Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.

 

16

 

 

9. ACCRUED EXPENSES AND LONG-TERM LIABILITIES

 

Other accrued expenses consisted of the following as of March 31, 2022 and December 31, 2021:

 

   March 31, 2022   December 31, 2021 
   (unaudited)     
Accrued royalties  $4,116   $3,890 
Contingent consideration   488    488 
Operating lease liability   999    1,041 
Financing lease liability   70    79 
Deferred revenue   31    40 
Interest payable   62    120 
Warrant liability   8    71 
Accrued sales and marketing - diagnostics   63    47 
Accrued lab costs - diagnostics   185    228 
Accrued professional fees   707    932 
Taxes payable   269    245 
Unclaimed property   565    565 
All others   1,129    1,452 
Total other accrued expenses  $8,692   $9,198 

 

Long-term liabilities consisted of the following as of March 31, 2022 and December 31, 2021:

 

   March 31, 2022   December 31, 2021 
   (unaudited)     
Uncertain tax positions  $4,631   $4,577 
Deferred revenue   13    13 
Other   41    58 
Total other long-term liabilities  $4,685   $4,648 

 

10. STOCK-BASED COMPENSATION

 

Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to Board members and employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.

 

The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the three-month periods ended March 31, 2022 and 2021.

 

   March 31, 2022   March 31, 2021 
    (unaudited) 
Risk-free interest rate   1.76%   0.78%
Expected life   6.0 years    6.0 years 
Expected volatility   129.93%   134.79%
Dividend yield   -    - 

 

17

 

 

During March 2021, the Company granted 312,500 stock options with an exercise price of $6.00 and 152,500 RSUs. The market value of the Company’s common stock was $5.00 at the grant date of these awards. The Company recognized approximately $0.3 million and $0.3 million of stock-based compensation expense during the three-month periods ended March 31, 2022 and 2021, respectively. The following table has a breakout of stock-based compensation expense by line item.

   Three Months Ended 
   March 31, 
   2022   2021 
    (unaudited)
Cost of revenue  $27   $48 
Sales and marketing   44    47 
Research and development   -    35 
General and administrative*   254    156 
Total stock compensation expense  $325   $286 

 

*Includes ESPP expense

 

11. INCOME TAXES

 

Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company’s valuation allowance position, it is the Company’s position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The following table summarizes income tax expense on loss from continuing operations and the effective tax rate for the three-month periods ended March 31, 2022 and 2021:

   2022   2021 
   Three Months Ended 
   March 31, 
   2022   2021 
   (unaudited) 
           
Provision for income tax  $18   $15 
Effective income tax rate   (0.8%)   (0.4%)

 

Income tax expense for both the three-month periods ended March 31, 2022 and 2021 was primarily due to minimum state and local taxes.

 

12. SEGMENT INFORMATION

 

We operate under one segment which is the business of developing and selling clinical and pharma services.

 

13. DISCONTINUED OPERATIONS

 

The components of liabilities classified as discontinued operations consist of the following as of March 31, 2022 and December 31, 2021:

 

   March 31, 2022   December 31, 2021 
   (unaudited)     
         
Accrued liabilities   766    766 
Current liabilities from discontinued operations   766    766 
Total liabilities  $766   $766 

 

18

 

 

The table below presents the significant components of CSO’s results included within loss from discontinued operations, net of tax in the condensed consolidated statements of operations for the three-months ended March 31, 2022 and 2021.

 

   2022   2021 
   Three Months Ended 
   March 31, 
   2022   2021 
   (unaudited) 
Income from discontinued operations, before tax  $-   $- 
Income tax expense   54    54 
Loss from discontinued operations, net of tax  $(54)  $(54)

 

14. NOTES PAYABLE

 

BroadOak Loan

 

On October 29, 2021, the Company and its subsidiaries entered into a Loan and Security Agreement (the “BroadOak Loan Agreement”) with BroadOak, providing for a term loan in the aggregate principal amount of $8,000,000 (the “Term Loan”). Funding of the Term Loan took place on November 1, 2021. The Term Loan matures upon the earlier of (i) October 31, 2024 or (ii) the occurrence of a change in control, and bears interest at the rate of 9% per annum. The Term Loan is secured by a security interest in substantially all of the Company’s and its subsidiaries’ assets and is subordinate to the Company’s $7,500,000 revolving credit facility with Comerica Bank. The Term Loan had an origination fee of 3% of the Term Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii) 30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the Term Loan, or if the Term Loan is repaid on its maturity date.

 

The BroadOak Loan Agreement contains affirmative and negative restrictive covenants that are applicable from and after the date of the Term Loan advance. These restrictive covenants, which include restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business. The BroadOak Loan Agreement also contains customary events of default.

 

In connection with the BroadOak Loan Agreement, the Company and its subsidiaries entered into that certain First Amendment to Loan and Security Agreement and Consent with Comerica, dated as of November 1, 2021 (the “Comerica Amendment”), pursuant to which Comerica consented to the Company’s and its subsidiaries’ entry into the BroadOak Loan Agreement, and amended that certain Loan and Security Agreement among Comerica, the Company and its subsidiaries (the “Comerica Loan Agreement”) to, among other things, permit the indebtedness, liens and encumbrances contemplated by the BroadOak Loan Agreement.

 

As a condition for BroadOak to extend the Term Loan to the Company and its subsidiaries, the Company’s existing creditor, Comerica, and BroadOak entered into that certain Subordination and Intercreditor Agreement, dated as of November 1, 2021, pursuant to which BroadOak agreed to subordinate all of the indebtedness and obligations of the Company and its subsidiaries owing to BroadOak to all of the indebtedness and obligations of the Company and its subsidiaries owing to Comerica (the “Intercreditor Agreement”). BroadOak further agreed to subordinate all of its respective security interests in assets or property of the Company and its subsidiaries to Comerica’s security interests in such assets or property. The Intercreditor Agreement provides that it is solely for the benefit of BroadOak and Comerica and is not for the benefit of the Company or any of its subsidiaries.

 

19

 

 

The Company concluded that the Note met the definition of a “recognized financial liability” which is an acceptable financial instrument eligible for the fair value option under ASC 825-10-15-4, and did not meet the definition of any of the financial instruments listed within ASC 825-10-15-5 that are not eligible for the fair value option. The Note is not convertible and does not have any component recorded to shareholders’ equity. Accordingly, the Company elected the fair value option for the Note.</